Drug
Pomalidomide clinical trials
Also written Pomalyst, CC-4047 and Imnovid.
- studies test it
- 181
- open now
- 38
- in phase 3
- 17
- first study started
- 2003
Keep track of what changes. Save the pomalidomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- CC-4047
- 62
Studies by the year they started
181 studies that test it; most in 2022 (20)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 12 |
| 2013 | 10 |
| 2014 | 16 |
| 2015 | 9 |
| 2016 | 6 |
| 2017 | 10 |
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 17 |
| 2022 | 20 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 77
- Phase 2
- 110
- Phase 3
- 17
- Phase 4
- 3
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 65 · Other 116
Celgene (24) · National Cancer Institute (NCI) (10) · Mayo Clinic (10) · Janssen Research & Development, LLC (7) · Weill Medical College of Cornell University (5) · AbbVie (4) · Massachusetts General Hospital (4) · Amgen (4)
Often tested with
Tested in the same studies.
Dexamethasone (94) · Daratumumab (21) · Carfilzomib (17) · Bortezomib (12) · Lenalidomide (12) · Ixazomib (9) · Belantamab mafodotin (8) · Isatuximab (7)
Studies
Open first, then newest update. How each study uses pomalidomide is read from its arms, and is right about nine times in ten.
Testing it · 181
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Genentech, Inc.NCT04910568Written as Pomalidomide
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Pomalidomide
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingPhase 1National Cancer Institute (NCI)NCT04902443Written as Pomalidomide
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaRecruitingPhase 1University of Michigan Rogel Cancer CenterNCT07532525Written as Pomalidomide
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingPhase 2Hoffmann-La RocheNCT07825064Written as Pomalidomide
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingPhase 3CelgeneNCT05519085Written as Pomalidomide
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Pomalidomide
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as Pomalidomide
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingPhase 2University of ChicagoNCT05789303Written as Pomalidomide
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingPhase 1Canadian Myeloma Research GroupNCT07831122Written as Pomalidomide
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Pomalidomide
- Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaRecruitingPhase 2CellCentric Ltd.NCT07096778Written as Pomalidomide
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingPhase 2Emory UniversityNCT05208307Written as Pomalidomide
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingPhase 1National Cancer Institute (NCI)NCT05389423Written as Pomalidomide
- Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingPhase 4The First Hospital of Jilin UniversityNCT07760610Written as Pomalidomide
- Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.Not yet recruitingPhase 2Odense University HospitalNCT07757412Written as Teclistamab (Tec) and Pomalidomide (Pom)
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingPhase 2Polish Myeloma ConsortiumNCT07748689Written as Pomalidomide
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT07749365Written as hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Pomalidomide
See all 181 studies that test pomalidomide →
Given in every arm · 66 — pomalidomide is usual care beside what is tested
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Pomalidomide
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT07463807Written as Pomalidomide
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Pomalidomide
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as Pomalidomide
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Written as Pomalidomide
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingPhase 2GlaxoSmithKlineNCT07227311Written as Pomalidomide
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingPhase 1/2GlaxoSmithKlineNCT05714839Written as Pomalidomide
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruitingPhase 1/2AstraZenecaNCT06106945Written as Pomalidomide
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingPhase 1Montefiore Medical CenterNCT07720843Written as Pomalidomide
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Pomalidomide
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingPhase 3Hangzhou Sumgen Biotech Co., Ltd.NCT06508983Written as pomalidomide
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Pomalidomide
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Pomalidomide
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaRecruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07018050Written as Pomalidomide
- QLS4131 Combination Therapy in Malignant Plasma Cell NeoplasmsNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07560449Written as Pomalidomide
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06742138Written as Pomalidomide
- A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaRecruitingPhase 1/2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06554561Written as Pomalidomide
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 2University of Colorado, DenverNCT04925193Written as Pomalidomide
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04722146Written as Pomalidomide
- A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT05050097Written as Pomalidomide
Showing 20 of 66.
As the comparator · 20 — what is tested is compared with pomalidomide
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as Pomalidomide
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingPhase 1/2AbbVieNCT06953960Written as Pomalidomide
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolRecruitingPhase 1/2SanofiNCT04643002Written as Pomalidomide
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 3Regeneron PharmaceuticalsNCT05730036Written as Pomalidomide
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as Pomalidomide
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Pomalidomide Capsules
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingPhase 3PfizerNCT05020236Written as Pomalidomide
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as Pomalidomide
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingPhase 3BiocadNCT07742215Written as Daratumumab + pomalidomide + dexamethasone
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07569757Written as Pomalidomide Capsule
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07452198Written as Pomalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)RecruitingPhase 3Nanjing IASO Biotechnology Co., Ltd.NCT06464991Written as Pomalidomide
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingPhase 1/2Columbia UniversityNCT05451771Written as Pomalidomide
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Pomalidomide
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyTerminatedPhase 3Universitätsklinikum Hamburg-EppendorfNCT05675319Written as daratumumab/pomalidomide/dexamethasone (DPD)
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingPhase 3AbbVieNCT03539744Written as Pomalidomide
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedPhase 1/2Multiple Myeloma Research ConsortiumNCT04150965Written as Elotuzumab, pomalidomide, dexamethasone
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnPhase 3CelgeneNCT06232707Written as Pomalidomide
- A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideTerminatedPhase 3Oncopeptides ABNCT03151811Written as Pomalidomide
- A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT03170882Written as Pomalidomide
Codes
What other systems call pomalidomide · ClinicalTrials.gg INT004483
- MeSH (NLM) C467566pomalidomideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) D2UX06XLB5POMALIDOMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1369713Confirmed FDA, Wikidata
- Wikidata Q7227206pomalidomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72560PomalidomideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C467566 | pomalidomide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | D2UX06XLB5 | POMALIDOMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1369713 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7227206 | pomalidomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72560 | Pomalidomide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.